Back to top
more

Mylan N.V. (MYL)

(Delayed Data from NSDQ)

$28.01 USD

28.01
4,315,758

+0.33 (1.19%)

Updated May 3, 2019 04:00 PM ET

After-Market: $28.00 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Biogen (BIIB) Q4 Earnings Miss, Revenues Surpass Estimates

by Zacks Equity Research

Biogen's (BIIB) earnings lag estimates in the fourth quarter of 2020, while revenues surpass the same. Tecfidera generics continues to hurt sales. The company provides revenues guidance for 2021.

Tirthankar Chakraborty headshot

2 Stocks to Watch on Pfizer's 90% Effective COVID-19 Vaccine

by Tirthankar Chakraborty

Pfizer's (PFE) shares hit an all-time high during yesterday's trading session on its milestone COVID-19 vaccine news, while Moderna's (MRNA) soared on optimism as it applies a similar technology.

Theravance (TBPH) Drops on Q3 Earnings Miss, Revenues In Line

by Zacks Equity Research

Theravance (TBPH) falls more than 13% as it reports wider-than-expected loss for the third quarter of 2020. Revenues meet estimates.

Mylan's (MYL) Q3 Earnings Surpass Estimates, Sales Miss

by Zacks Equity Research

Mylan (MYL) beats on Q3 earnings but misses on sales. The company is all set to merge with Pfizer's Upjohn business later in the month.

Mylan (MYL) Q3 Earnings Surpass Estimates

by Zacks Equity Research

Mylan (MYL) delivered earnings and revenue surprises of 14.78% and -0.24%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

What's in the Cards for Enlivex (ENLV) This Earnings Season?

by Zacks Equity Research

Investors will be keen on pipeline updates when Enlivex Therapeutics (ENLV) reports results for the three months ending Sep 30, 2020.

Is a Disappointment in Store for Tilray's (TLRY) Q3 Earnings?

by Zacks Equity Research

Investors will focus on revenue growth and other pipeline updates, when Tilray (TLRY) reports third-quarter 2020 results.

Is a Disappointment in Store for Zosano (ZSAN) Q3 Earnings?

by Zacks Equity Research

Investors will be keen on updates on Qtrypta when Zosano (ZSAN) reports Q3 results.

Mylan (MYL) to Report Q3 Earnings: Is a Beat in the Cards?

by Zacks Equity Research

Investors will look forward to regular top and bottom-line numbers and updates on the merger with Upjohn, when Mylan (MYL) reports Q3 results.

TEVA Gears Up to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

On Teva's (TEVA) third-quarter conference call, investors will look for updates on the extent to which the coronavirus pandemic may have impacted sales of its products.

Why Mylan (MYL) Might Surprise This Earnings Season

by Zacks Equity Research

Mylan (MYL) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Will Mylan (MYL) Beat Estimates Again in Its Next Earnings Report?

by Zacks Equity Research

Mylan (MYL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Pfizer (PFE) Q3 Earnings Top, Sales Miss, View Narrowed

by Zacks Equity Research

Pfizer (PFE) beats estimates for earnings while missing the same for sales. It narrows its financial outlook for the year.

Biogen (BIIB) Q3 Earnings Top, Tecfidera Generics Hurt Sales

by Zacks Equity Research

Biogen (BIIB) beats third-quarter estimates for both earnings and sales. Tecfidera generics hurts sales, resulting in guidance cut.

Roche Buys NLRP3 Inflammasome Inhibitors Developer Inflazome

by Zacks Equity Research

Roche (RHHBY) buys Inflazome for ???euro 380 million and gains access to pipeline of small molecule NLRP3 inhibitors.

Mylan/Pfizer's Upjohn Unit Merger on Track to Close in Q4

by Zacks Equity Research

The pending merger of Pfizer's (PFE) Upjohn unit with Mylan (MYL) is on track to close in the fourth quarter of 2020 as almost all necessary regulatory clearances are in place.

Mylan to Buy Aspen Pharmacare's Thrombosis Business in Europe

by Zacks Equity Research

Mylan (MYL) will acquire Aspen Pharmacare's thrombosis business in Europe and expand its complex injectables offering and presence in hospitals.

Mylan (MYL) Down 3.7% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Mylan (MYL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Theravance (TBPH) Earnings & Revenues Miss Estimates in Q2

by Zacks Equity Research

Theravance (TBPH) reports worse-than-expected loss for the second quarter while revenues too miss the mark. The company reiterates its 2020 outlook.

Mylan (MYL) Q2 Earnings Beat Estimates, Revenues Fall Y/Y

by Zacks Equity Research

Mylan (MYL) beats on both earnings and revenues for the second quarter of 2020.

Endo (ENDP) Q2 Earnings & Sales Beat as Coronavirus Impacts Ease

by Zacks Equity Research

Endo's (ENDP) earnings and sales beat estimates in the second quarter as COVID-19-related restrictions ease out.

Teva (TEVA) Q2 Earnings Top, Stock Up Despite Coronavirus Woes

by Zacks Equity Research

Teva (TEVA) beats second-quarter estimates for earnings while missing the same for sales. It maintains its previously issued guidance for 2020. Stock up.

Mylan (MYL) Surpasses Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Mylan (MYL) delivered earnings and revenue surprises of 16.84% and 1.08%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Mylan (MYL) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Mylan (MYL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Glaxo (GSK) Q2 Earnings & Sales Miss Estimates, Decline Y/Y

by Zacks Equity Research

Glaxo (GSK) witnesses disruption from COVID-19 pandemic in Vaccines and reversal of stockpiling benefits from the first quarter in Pharmaceuticals and Consumer Healthcare, which hurt sales.